Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umbralisib - TG Therapeutics

Drug Profile

Umbralisib - TG Therapeutics

Alternative Names: RP 5307; RP-5264; TGR-1202; UKONIQ

Latest Information Update: 27 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incozen Therapeutics; Rhizen Pharmaceuticals
  • Developer TG Therapeutics Inc
  • Class Amines; Antineoplastics; Benzopyrans; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Casein kinase Iepsilon inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Follicular lymphoma; Marginal zone B-cell lymphoma
  • Preregistration Chronic lymphocytic leukaemia
  • Phase II/III Diffuse large B cell lymphoma; Mantle-cell lymphoma
  • Phase II Hodgkin's disease; Waldenstrom's macroglobulinaemia
  • Phase I/II Non-Hodgkin's lymphoma; Richter's syndrome
  • No development reported Multiple sclerosis; Myelofibrosis; Polycythaemia vera; Solid tumours

Most Recent Events

  • 23 Sep 2021 Pooled safety and efficacy data from phase I and phase II trials in Non-Hodgkin lymphoma, Follicular lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma, Lymphocytic leukemia released by TG Therapeutics
  • 23 Sep 2021 Updated adverse events data from a phase I/II trial in Chronic lymphocytic leukaemia released by TG therapeutics
  • 20 Sep 2021 Updated efficacy data from phase I/II trials in Chronic lymphocytic leukaemia released by TG Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top